1. Volume 84, Issue 2, Pages 366-372 (August 2013)
Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis 
Jing Huang, Gang Liu, Yi-Miao Zhang, Zhao Cui, Fang Wang, Xiao-Jing Liu, Rong Chu, Ying Chen, Ming-Hui Zhao 
Kidney International 
Volume 84, Issue 2, Pages (August 2013)
DOI: /ki
Copyright © 2013 International Society of Nephrology Terms and Conditions

2. Figure 1
Plasma soluble urokinase-type plasminogen activator receptor (suPAR) levels among patients with primary focal segmental glomerulosclerosis (FSGS), normal subjects, and patients with minimal change disease, membranous nephropathy, and secondary FSGS.
Kidney International  , DOI: ( /ki )
Copyright © 2013 International Society of Nephrology Terms and Conditions

3. Figure 2
The plasma soluble urokinase-type plasminogen activator receptor (suPAR) levels in primary focal segmental glomerulosclerosis (FSGS) patients with different pathological variants. NOS, not otherwise specified.
Kidney International  , DOI: ( /ki )
Copyright © 2013 International Society of Nephrology Terms and Conditions

4. Figure 3
The correlations between plasma soluble urokinase-type plasminogen activator receptor (suPAR) level and creatinine clearance rate for the individual glomerular disease. (a) Patients with primary focal segmental glomerulosclerosis (FSGS), (b) patients with minimal change disease, (c) patients with membranous nephropathy, and (d) patients with secondary FSGS.
Kidney International  , DOI: ( /ki )
Copyright © 2013 International Society of Nephrology Terms and Conditions

5. Figure 4
The changes in plasma soluble urokinase-type plasminogen activator receptor (suPAR) level in patients with primary focal segmental glomerulosclerosis (FSGS) during follow-up. (a) Patients with complete remission, (b) patients with partial remission, and (c) patients with treatment failure.
Kidney International  , DOI: ( /ki )
Copyright © 2013 International Society of Nephrology Terms and Conditions